CRISPR Therapeutics AG
Close on Oct 19, 2026
- Market cap
- $4.83B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | After market close | $10.18M | $-0.94 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | After market close | $1.46M | $-1.28 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | After market close | $864.00K | $-1.37 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | $889.00K | $-1.17 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | After market close | $892.00K | $-2.40 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $865.00K | $-1.58 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 11, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | Before market open | $602.00K | $-1.01 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 21, 2024 | Before market open | – | – | – |
Press releases
Announcements CRISPR Therapeutics filed with the SEC
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
Other events · EX-99.1 to Form 8-K
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
Other events · EX-99.2 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Announces Leadership Transition
Executive or director change · Other events · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Regulation FD disclosure · Other events · EX-99 to Form 8-K
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
Material agreement · Regulation FD disclosure · EX-99 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Innovation Day June 21, 2022 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT-LYM Trial of CTX130 in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Acknowledgments Thank you to all the patients, families and investigators involved with the COBALT-LYM Study This study was sponsored by CRISPR Therapeutics COBALT-LYM (NCT04502446) Study Sites Presented at the European Hematology Association Annual Meeting. 11 June 2022
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130 for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
25. Gene therapy, cellular immunotherapy and vaccination - Clinical
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110 for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies
Regulation FD disclosure · EX-99.1 to Form 8-K
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Updated Results from the Phase 1 CARBON
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K